BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 1597723)

  • 21. A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer.
    Wong JY; Shibata S; Williams LE; Kwok CS; Liu A; Chu DZ; Yamauchi DM; Wilczynski S; Ikle DN; Wu AM; Yazaki PJ; Shively JE; Doroshow JH; Raubitschek AA
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5842-52. PubMed ID: 14676105
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer.
    Knox SJ; Goris ML; Tempero M; Weiden PL; Gentner L; Breitz H; Adams GP; Axworthy D; Gaffigan S; Bryan K; Fisher DR; Colcher D; Horak ID; Weiner LM
    Clin Cancer Res; 2000 Feb; 6(2):406-14. PubMed ID: 10690517
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
    Brouwers AH; van Eerd JE; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC
    J Nucl Med; 2004 Feb; 45(2):327-37. PubMed ID: 14960657
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of hormone-refractory prostate cancer with 90Y-CYT-356 monoclonal antibody.
    Deb N; Goris M; Trisler K; Fowler S; Saal J; Ning S; Becker M; Marquez C; Knox S
    Clin Cancer Res; 1996 Aug; 2(8):1289-97. PubMed ID: 9816299
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dosimetric analysis of radioimmunotherapy with 186Re-labeled bivatuzumab in patients with head and neck cancer.
    Postema EJ; Börjesson PK; Buijs WC; Roos JC; Marres HA; Boerman OC; de Bree R; Lang M; Munzert G; van Dongen GA; Oyen WJ
    J Nucl Med; 2003 Oct; 44(10):1690-9. PubMed ID: 14530488
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reinfusion of unprocessed, granulocyte colony-stimulating factor-stimulated whole blood allows dose escalation of 186Relabeled chimeric monoclonal antibody U36 radioimmunotherapy in a phase I dose escalation study.
    Colnot DR; Ossenkoppele GJ; Roos JC; Quak JJ; de Bree R; Börjesson PK; Huijgens PC; Snow GB; van Dongen GA
    Clin Cancer Res; 2002 Nov; 8(11):3401-6. PubMed ID: 12429627
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical evaluation of indium-111-labeled chimeric anti-CEA monoclonal antibody.
    Wong JY; Thomas GE; Yamauchi D; Williams LE; Odom-Maryon TL; Liu A; Esteban JM; Neumaier M; Dresse S; Wu AM; Primus FJ; Shively JE; Raubitschek AA
    J Nucl Med; 1997 Dec; 38(12):1951-9. PubMed ID: 9430476
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pretargeted radioimmunotherapy of human colorectal xenografts with bispecific antibody and 131I-labeled bivalent hapten.
    Gautherot E; Rouvier E; Daniel L; Loucif E; Bouhou J; Manetti C; Martin M; Le Doussal JM; Barbet J
    J Nucl Med; 2000 Mar; 41(3):480-7. PubMed ID: 10716323
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ablation of human colon carcinoma in nude mice by 131I-labeled monoclonal anti-carcinoembryonic antigen antibody F(ab')2 fragments.
    Buchegger F; Pfister C; Fournier K; Prevel F; Schreyer M; Carrel S; Mach JP
    J Clin Invest; 1989 May; 83(5):1449-56. PubMed ID: 2708519
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
    Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
    Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative evaluation of capsular polysaccharide-specific IgM and IgG antibodies and F(ab')2 and Fab fragments as delivery vehicles for radioimmunotherapy of fungal infection.
    Dadachova E; Bryan RA; Huang X; Ortiz G; Moadel T; Casadevall A
    Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5629s-5635s. PubMed ID: 17875799
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin.
    Koppe MJ; Bleichrodt RP; Soede AC; Verhofstad AA; Goldenberg DM; Oyen WJ; Boerman OC
    J Nucl Med; 2004 Jul; 45(7):1224-32. PubMed ID: 15235070
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Monoclonal antibodies labeled with rhenium-186 using the MAG3 chelate: relationship between the number of chelated groups and biodistribution characteristics.
    van Gog FB; Visser GW; Klok R; van der Schors R; Snow GB; van Dongen GA
    J Nucl Med; 1996 Feb; 37(2):352-62. PubMed ID: 8667076
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I radioimmunotherapy trial with iodine-131-CC49 in metastatic colon carcinoma.
    Divgi CR; Scott AM; Dantis L; Capitelli P; Siler K; Hilton S; Finn RD; Kemeny N; Kelsen D; Kostakoglu L
    J Nucl Med; 1995 Apr; 36(4):586-92. PubMed ID: 7699446
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fractionated radioimmunotherapy of intraperitoneally growing ovarian cancer in nude mice with 211At-MX35 F(ab')2: therapeutic efficacy and myelotoxicity.
    Elgqvist J; Andersson H; Bäck T; Claesson I; Hultborn R; Jensen H; Lindegren S; Olsson M; Palm S; Warnhammar E; Jacobsson L
    Nucl Med Biol; 2006 Nov; 33(8):1065-72. PubMed ID: 17127181
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Radioimmunotherapy for breast cancer using escalating fractionated doses of 131I-labeled chimeric L6 antibody with peripheral blood progenitor cell transfusions.
    Richman CM; DeNardo SJ; O'Grady LF; DeNardo GL
    Cancer Res; 1995 Dec; 55(23 Suppl):5916s-5920s. PubMed ID: 7493370
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Initial experience evaluating 90yttrium-radiolabeled anti-carcinoembryonic antigen chimeric T84.66 in a phase I radioimmunotherapy trial.
    Wong JY; Williams LE; Yamauchi DM; Odom-Maryon T; Esteban JM; Neumaier M; Wu AM; Johnson DK; Primus FJ; Shively JE
    Cancer Res; 1995 Dec; 55(23 Suppl):5929s-5934s. PubMed ID: 7493373
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics and normal organ dosimetry following intraperitoneal rhenium-186-labeled monoclonal antibody.
    Breitz HB; Durham JS; Fisher DR; Weiden PL; DeNardo GL; Goodgold HM; Nelp WB
    J Nucl Med; 1995 May; 36(5):754-61. PubMed ID: 7738644
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Radioimmunotherapy of human colon cancer xenografts by using 131I labeled-CAb1 F(ab')2.
    Li L; Xu HY; Mi L; Bian HJ; Qin J; Xiong H; Feng Q; Wen N; Tian R; Xu LQ; Shen XM; Tang H; Chen ZN
    Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):1238-44. PubMed ID: 16979831
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preclinical evaluation of 67Cu-labeled intact and fragmented anti-colon carcinoma monoclonal antibody MAb35.
    Smith A; Alberto R; Blaeuenstein P; Novak-Hofer I; Maecke HR; Schubiger PA
    Cancer Res; 1993 Dec; 53(23):5727-33. PubMed ID: 8242629
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.